In this context, recent studies have reported that vemurafenib, by specifically inhibiting mutant BRAF signalling, results in tumour regressions [7] and improved both overall and progression-free survivals in patients with metastatic melanoma harbouring the V600EBRAF mutation [8]. Here, BRAF is linked to neoplasm.